The EpiVax Team


Rich-Henry Schabowsky, PhD JD


Rich-Henry Schabowsky, PhD, JD, has recently joined EpiVax leadership as Chief Executive Officer. His extensive experience and diverse skill set make him an outstanding choice for the CEO position, promising to drive innovation and growth.

Rich-Henry holds a bachelor’s degree in economics, a master’s and Ph.D. in Microbiology and Immunology, as well as a J.D. Starting his career as a researcher in vaccine development, he later became a partner and registered patent attorney at Dinsmore & Shohl LLP, specializing in IP protection for life science, biotech, and tech companies.

Joining EpiVax in 2021 as the Scientific and Intellectual Property Director, he spearheaded the company’s IP strategy for protecting immunoinformatics tools and therapeutics developed therefrom. More recently, he took on the role of partner at Thursday Ventures, a venture firm investing in early-stage frontier technology. He also recently served as CEO of Thursday’s talent acquisition firm, Towerhill Associates, and currently sits on the board of Biobot Analytics. Rich-Henry’s multidisciplinary background uniquely positions him at the intersection of science, law, and operations.
Beyond his corporate endeavors, Rich-Henry is actively involved in community service, serving on the board of Clínica Esperanza/Hope Clinic and teaching Brazilian jiu-jitsu to youth in his local community.


Anne (Annie) S. De Groot, M.D.


Anne De Groot is internationally known for her research on the human immune system’s response to vaccines and therapeutics. She graduated from Smith College in 1978 and earned her medical degree at University of Chicago in 1983. After internal medical residency, she obtained advanced training in immunoinformatics and vaccinology with Michael Good, Russell Howard and Jay Berzofsky at the National Institutes of Health, and then returned for a fellowship in ID at New England Medical Center.

Research Gate Profile

Google Scholar Profile

PubMed Bibliography


Read More

Senior Professor (Research), University of Georgia Center for Vaccines and Immunology Founder/Scientific Director GAIA Vaccine Foundation Volunteer Medical Director Clínica Esperanza /Hope Clinic. She then moved to Brown University, establishing the TB/HIV Research Lab as an emerging center for immune-informatics driven Vaccine design. EpiVax spun out from that laboratory in 1998 and she gradually shifted her effort from 20% to 80% effort at the company. In 2008, she was invited to move her academic affiliation from Brown University to University of Rhode Island, in order to establish the Institute for Immunology and Informatics (iCubed). In 2020, Dr. De Groot joined the University of Georgia as a Senior Professor (Research) in the College of Veterinary Medicine/Center for Vaccines and Immunology. She has been the recipient of many awards for her groundbreaking work at the intersection of immunology and informatics and is recognized as an early adopter of this technology and an evangelist for the use of immunoinformatics to improve vaccines and protein therapeutics. She has won many awards for her work, including most recently, the Smith Medal (2013). Her work focuses on harnessing the power of T cells to modulate immune responses, whether to improve vaccines or to reduce the immunogenicity of protein therapeutics. In collaboration with the innovative scientists at EpiVax, she has worked to develop and validate a set of immunoinformatics tools that dramatically accelerate the development of vaccines directly from genomic sequences. With Bill Martin, Dr. Lenny Moise, Dr. Christine Boyle and Frances Terry, she works on a number of projects related to the development and application of the genome-to-vaccine iVAX toolkit, and with Bill Martin, Frances Terry, and Guilhem Richard of the Immunoinformatics team she coordinates the application of ISPRI tools to screening protein therapeutics for immunogenicity. With BD Representative Sarah Moniz, she coordinates ISPRI and iVAX services for a global list of Pharma clients. She collaborates with Sandra Lelias to drive Tregitope technology forward, working to develop Tregitope as a stand-alone drug and as an immunomodulators for application to specific autoimmune diseases. With Dr. Lenny Moise, she coordinates the application of EpiVax tools to improving Protein Therapeutics like Botulinum Toxin and monoclonal antibodies such as Campath.

William Martin


William Martin is the principal architect and developer of the EpiMatrix System. Building on the work done in Dr. De Groot’s Brown University laboratory, Mr. Martin has revised and expanded the EpiMatrix toolkit. In addition to developing new and improved predictive matrices for many Class I and Class II HLA alleles, Mr. Martin has developed a suite of protocols, ancillary tools and database structures allowing for fast and efficient analysis of input protein sequences.

Brad Crevier, JD


Brad Crevier, JD, is responsible for managing all strategic financial objectives at EpiVax, providing crucial financial information and operational analytics to the executive team. He has a wealth of financial management experience, most recently as Assistant Treasurer at audio technology company Sonos, where he also held the positions of Director of Treasury and Director of International Tax, contributing to the company’s successful IPO. Additionally, Brad has previous experience at PE-backed The Rockport Group and the Boston offices of Deloitte and PwC.  He is a bar-certified attorney with a JD and MSA/MBA from Northeastern University.

As a senior global finance executive, Brad brings deep expertise in corporate and capital structuring, finance policy implementation, treasury operations, tax strategy, and risk management across diverse business landscapes.

Amy Rosenberg, M.D.


Amy Rosenberg is a physician immunologist with extensive expertise in development and immunogenicity of therapeutic protein and cellular products. During her 30+ years at the FDA, Amy was principal or intimately involved in the regulation and approval of numerous FDA regulated products. Amy joined EpiVax in September 2021 as Senior Director of Immunology and Protein Therapeutics.

Read More

During her time at the FDA, Amy oversaw the regulation of many therapies, including hematopoietic stem cells and their selection devices, therapeutic proteins including monoclonal antibodies and fusion proteins, enzyme replacement therapies, immunomodulators including interleukins and interferons, hematologic and somatic cell growth factors, and combination devices-biologics. Additionally, Amy served on the FDA’s Oncology Center of Excellence Science Council. Amy was also an FDA consultant to the Immune Tolerance Network (NIAID) and to the ABIRISK consortium. At EpiVax, Amy is a wealth of knowledge for clients looking to address immunogenicity risk in anticipation of regulatory filing. She now heads up the EpiVax TEA consulting service (Trusted Expert Advice) and provides consulting to clients on a one-on-one basis on relevant aspects of the FDA regulatory process as it relates to the client’s pipeline and projects.

Aimee Mattei, MS


Aimee manages a team of analysts and project managers providing in silico immunogenicity risk assessments supporting research, collaborative, and commercial projects.

She leads the development of novel in silico methods and tools for assessing immunogenic risk of peptide impurities, including sequences containing unnatural amino acids. She holds an M.S. in Pharmaceutical Chemistry and has previous experience in the design, synthesis, purification, and characterization of peptides supporting research programs from concept assessment through lead optimization in the endocrinology and oncology therapeutic areas.

Matthew Ardito


In his early years at EpiVax, Matthew Ardito assisted in maintaining applications associated with the design and reengineering of protein therapeutics and antibody structures, as well as genome mining, epitope mapping, and vaccine design. In 2016, Matt was promoted to Principal Applications Developer and Codebase Manager, where he led a team of developers in the design, development, implementation, testing, and deployment of immunoinformatics applications. In 2021, Matt was promoted again to Director of IT, where he is responsible for the management, strategy, and execution related to the maintenance of IT infrastructure at EpiVax.

Read More

Matthew Ardito joined EpiVax in the Spring of 2008, two days after obtaining his Bachelor’s in both Computer Science and Mathematics at Rhode Island College. In his early years at EpiVax, Matt assisted in maintaining applications associated with the design and reengineering of protein therapeutics and antibody structures, as well as genome mining, epitope mapping, and vaccine design. As the lead analyst, he used in-silico tools and custom-made driver scripts for client- and grant-based projects ranging from predicted antibody/therapeutic immunogenicity and deimmunization to the formulation of genome-derived, epitope-driven vaccines. In 2016, Matt was promoted to Principal Applications Developer and Codebase Manager, where he led a team of developers in the design, development, implementation, testing, and deployment of immunoinformatics applications relevant to ISPRI (antibody re-engineering pipeline), IVAX (epitope-based vaccine design pipeline), ISPRI_HCP (host cell protein immunogenicity), matrix development, and ANCER (personalized cancer vaccine) web platforms. In 2021, Matt was promoted again to Director of IT, where he is currently responsible for the management, strategy, and execution related to the maintenance of IT infrastructure at EpiVax. Matt oversees all IT functions including, but not limited to: designing, securing and implementing information systems, leading the growth and expansion of all internal application development, devising and establishing all IT-related policies and procedures, and supervising a team of IT professionals tasked with ensuring the company’s technology operations run efficiently.

Brian J. Roberts, Ph.D.


Brian Roberts is the scientific director of the Preclinical Immunology program. Dr. Roberts received his PhD in Cell and Molecular Biology from the University of Vermont in 2012. His research in the laboratory of Dr Sally Huber focused on the role of toll-like receptors in sex differences in viral-induced autoimmune myocarditis. Dr. Roberts joined EpiVax in 2015 as a postdoctoral researcher working primarily with the Tregitope team. In 2018 he became manager of the Protein Therapeutics group at EpiVax, and oversees the PANDA projects.

Read More

A full list of Dr. Roberts’ publications can be found below: De Groot AS, Rosenberg AS, Miah SMS, Skowron G, Roberts BJ, Lélias S, Terry FE, Martin WD. Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses. Clin Immunol. 2021 Mar;224:108661. doi: 10.1016/j.clim.2020.108661. Epub 2021 Jan 4. PMID: 33412295. Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, De Groot AS. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020. Front Immunol. 2020 Jun 30;11:1301. doi: 10.3389/fimmu.2020.01301. PMID: 32695107; PMCID: PMC7338774. Iwona A Buskiewicz, Andreas Koenig, Brian Roberts, Jennifer Russell, Cuixia Shi, Sun-Hwa Lee, Jae U. Jung, Sally A Huber, and Ralph C Budd. “c-FLIP-Short Reduces Type I Interferon Production and Increases Viremia with Coxsackievirus B3”. PLoS ONE 2014 9:5, pages e96156 Roberts, Brian J., Mohamad Moussawi, and Sally A. Huber. “Sex differences in TLR2 and TLR4 expression and their effect on coxsackievirus-induced autoimmune myocarditis.” Experimental and Molecular Pathology 2013 94:1 Roberts, Brian J., Julie Dragon, Mohamad Moussawi, and Sally A. Huber. “Sex-specific signaling through toll-like receptors 2 and 4 contributes to survival outcome of Coxsackievirus B3 infection in C57Bl/6 mice. Biology of Sex Differences 2012 3:25 Huber, Sally A, Brian Roberts, Mohamad Moussawi and Jon Boyson. Slam Haplotype 2 Promotes NKT but Suppresses Vg4 T-cell Activation in Coxsackievirus B3 infection Leading to Increased Liver Damage but Reduced Myocarditis. American Journal of Pathology. Available online November 27, 2012 Case, Laure K., Leon Toussaint, Mohamad Moussawi, Brian Roberts, Naresha Saligrama, Laurent Brossay, Sally A. Huber, and Cory Teuscher. “Chromosome Y regulates survival following murine coxsackievirus B3 infection.” G3: Genes| Genomes| Genetics 2, no. 1 (2012): 115-121. Liu, Wei, Oliver Dienz, Brian Roberts, Mohamad Moussawi, Mercedes Rincon, and Sally A. Huber. “IL-21R expression on CD8+ T cells promotes CD8+ T cell activation in coxsackievirus B3 induced myocarditis.” Experimental and molecular pathology 92 no. 3(2012): 327-333 Case, Laure K., Mohamad Moussawi, Brian Roberts, Rajkumar Noubade, Sally A. Huber, and Cory Teuscher. “Histamine H< sub> 1 receptor signaling regulates effector T cell responses and susceptibility to coxsackievirus B3-induced myocarditis.” Cellular immunology 272 no.2 (2011): 269-274 Robinson, Dionne P., Sally A. Huber, Mohamad Moussawi, Brian Roberts, Cory Teuscher, Rebecca Watkins, Arthur P. Arnold, and Sabra L. Klein. “Sex chromosome complement contributes to sex differences in coxsackievirus B3 but not influenza A virus pathogenesis.” Biology of sex differences 2, no. 1 (2011): 1-11. Fong, P. P., Philbert, C. M. and Roberts, B. J. (2003), Putative serotonin reuptake inhibitor-induced spawning and parturition in freshwater bivalves is inhibited by mammalian 5-HT2 receptor antagonists. J. Exp. Zool., 298A: 67–72. doi: 10.1002/jez.a.10279